Search
Chlorquinaldol
go.drugbank.com/drugs/DB13306Approved[F4549] It was marketed in the 1950s as an iodine-free alternative which was also unrelated to sulfa drugs or hormones. … Chlorquinaldol is currently approved by the European Medicines Agency as a combination tablet with promestriene for the treatment of bacterial vaginosis.[F4552]
Lasofoxifene
go.drugbank.com/drugs/DB06202ApprovedInvestigationalWithdrawnIt was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. … It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.
Ketoconazole
go.drugbank.com/drugs/DB01026ApprovedInvestigational[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. … Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Categories: Antifungals for Topical Use, Antimycotics for Systemic UseProducts: KETOCONAZOL POR 200 MG TABLETAS, REKET - KETOCONAZOL TABLETAS X 200 MGAndusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigationalAndusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. … [elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Synonyms: CX-038839 Omicron (XBB.1.5)Bromotheophylline
go.drugbank.com/drugs/DB14018Approved[L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.
Categories: Drugs for Obstructive Airway DiseasesTafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigationalfor the treatment of relapsed or refractory DLBCL in adult patients who cannot receive autologous stem cell transplants. … Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies.
Protein S100-A12
go.drugbank.com/bio_entities/BE0001206TargetHumansS100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. … Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to receptor for advanced glycation endproducts (AGER).
Synonyms: Calcium-binding protein in amniotic fluid 1Palifermin
go.drugbank.com/drugs/DB00039ApprovedInvestigationalPalifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.[L17933]
Categories: Detoxifying Agents for Antineoplastic TreatmentArimoclomol
go.drugbank.com/drugs/DB05025Approved[L51384] Arimoclomol was approved by the FDA on September 20, 2024, making it the first treatment for Niemann-Pick disease, type C (NPC). … [L51389] It is also being investigated in amyotrophic lateral sclerosis (ALS) [A264414, A264429] and inclusion body myositis.[A264419]
Synonyms: 3-PYRIDINECARBOXIMIDOYL CHLORIDE, N-((2R)-2-HYDROXY-3-(1-PIPERIDINYL)PROPOXY), 1-OXIDE, N-[(2R)-2-Hydroxy-3-(1-piperidyl)propoxy]pyridine-3-carboximidoyl chloride, 1-oxideOxcarbazepine
go.drugbank.com/drugs/DB00776ApprovedInvestigationalOxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000. … [A186011] Compared to other anti-epileptic drugs, which are generally metabolized via the cytochrome P450 system, oxcarbazepine has a reduced propensity for involvement in drug-drug interactions owing
Products: Oxtellar XR, KALLION XR